Alkermes PLC 8-K filings

Alkermes plc announced an amendment to its credit agreement, reducing interest rates on its term loan facilities.

Alkermes plc amends prior filing to detail compensation and board appointment for Blair C. Jackson as he assumes President and CEO roles.

Alkermes plc announced its second quarter 2026 financial results, reporting $496.0 million in revenue and $139.2 million in Adjusted EBITDA, while also announcing a CEO transition effective August 1, 2026.

Alkermes plc announced the termination of its Authorized Generic Product Supply Agreement with Amneal Pharmaceuticals LLC for a generic version of VIVITROL, effective July 6, 2026.

Alkermes plc announced that its investigational drug, alixorexton, has received orphan drug designations from the FDA for idiopathic hypersomnia and the European Commission for narcolepsy.

Alkermes plc shareholders approved amendments to the 2018 Stock Option and Incentive Plan, increasing authorized shares and re-electing directors at the annual meeting.

Alkermes plc reported positive topline results from its Phase 3 REVITALYZ study, showing LUMRYZ significantly improved symptoms of idiopathic hypersomnia.

Alkermes plc announced its first quarter 2026 financial results, reporting total revenues of $392.9 million and updating its full-year financial expectations following the acquisition of Avadel Pharmaceuticals.

Alkermes plc has finalized its acquisition of Avadel Pharmaceuticals, integrating the narcolepsy treatment LUMRYZ into its commercial portfolio.

Alkermes plc announces CEO Richard Pops will retire in July 2026 after 35 years, with current COO Blair Jackson appointed as his successor.

Alkermes plc reported strong financial results for 2025, driven by proprietary product growth, and outlined 2026 expectations including the integration of the Avadel acquisition and advancement of its neuroscience pipeline.

Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc, adding the narcolepsy treatment LUMRYZ and accelerating its entry into the sleep medicine market.

Alkermes plc reported preliminary 2025 revenues exceeding $1.45 billion and outlined strategic growth plans, including the acquisition of Avadel and advancement of its orexin pipeline.

Alkermes plc announced that its investigational drug, alixorexton, received Breakthrough Therapy designation from the U.S. FDA for the treatment of narcolepsy type 1.

Alkermes plc has increased its recommended offer to acquire Avadel Pharmaceuticals plc to $21.00 cash plus a $1.50 CVR per share, valuing the transaction at up to $2.37 billion.

Alkermes plc announced positive topline results from its Vibrance-2 Phase 2 study of alixorexton for narcolepsy type 2, demonstrating significant improvements in wakefulness and sleepiness.

Alkermes plc reported robust third-quarter financial results, driven by strong proprietary product sales, and subsequently raised its full-year 2025 financial expectations.

Alkermes plc announced a definitive agreement to acquire Avadel Pharmaceuticals plc for up to $2.1 billion, including a contingent value right, to expand its commercial presence in the sleep medicine market with LUMRYZ.

Alkermes plc announced an authorized generic supply agreement for VIVITROL and filed patent infringement lawsuits to protect its LYBALVI intellectual property.

Alkermes plc announced the appointment of Joshua Reed, a seasoned biopharmaceutical finance executive, as its new Chief Financial Officer, effective September 15, 2025.

Alkermes plc announced detailed positive results from its Vibrance-1 Phase 2 study of alixorexton for narcolepsy type 1, demonstrating significant improvements in wakefulness, cognition, and fatigue.

Alkermes plc announced its second quarter 2025 financial results, showcasing robust growth in proprietary product sales and positive Phase 2 clinical data for its narcolepsy candidate, alixorexton, while overall revenue declined due to an expired royalty agreement.

Alkermes plc announced positive topline results from its Vibrance-1 Phase 2 study of alixorexton, demonstrating significant improvements in wakefulness and patient-reported outcomes for narcolepsy type 1 patients, supporting advancement to Phase 3.

Alkermes plc shareholders approved amendments to the 2018 Stock Option and Incentive Plan, increasing the authorized shares for issuance by 4,250,000, and elected directors at the 2025 annual general meeting.

Alkermes plc announced its first quarter 2025 financial results, reporting revenues of $306.5 million and reiterating its financial expectations for the year.

Alkermes plc reports the passing of Chief Financial Officer Iain M. Brown on April 14, 2025, after his battle with cancer.

Alkermes plc announces positive financial results for 2024, driven by increased proprietary product sales, and sets financial expectations for 2025, focusing on neuroscience and pipeline development.

Alkermes is projecting a profitable 2025, driven by proprietary products and advancements in their orexin agonist pipeline, particularly ALKS 2680.

Alkermes, Inc., a subsidiary of Alkermes plc, has fully prepaid and terminated its Amended and Restated Credit Agreement, effective December 19, 2024.

Alkermes is focusing on its four core products and advancing its neuroscience pipeline, aiming for sustained profitability and significant cash generation.